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ABSTRACT
ABBREVIATIONS: KATP, ATP-sensitive potassium channel; VF, ventricular fibrillation; VT, ventricular tachycardia; VEB, ventricular extrasystole.
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We investigated the effects of pinacidil, an ATP-sensitive po-
tassium channel opener, and of glibenclamide, an ATP-sensi-
tive potassium channel inhibitor, on the incidence of arrhyth-
mias and sudden cardiac death after coronary artery ligation in
conscious rats. Occlusion of the left main coronary artery was
produced by tightening a previously placed loose silk ligature.
In the control group (n = 25) only 40% and 24% of the animals
survived for 1 5 mm and 1 6 hr after coronary artery ligation,
respectively. Intravenous pretreatment with 0.1 , 0.3 or 1 mg/kg
pinacidil increased the survival rate to 67% (n = 15), 70% (n =
20) and 67% (n = 12) in the first15 mm and to 60%, 55% and
67% in the first 1 6 hr, respectively. Glibenclamide pretreatment
(5.0 mg/kg i.p.) improved the survival rate at both time-points to
87% (n = 16). Both types of pretreatment significantly de-
creased the incidence of life-threatening arrhythmias and in-
creased the number of animals that survived without develop-
ing any arrhythmia. In conclusion, the present findings
demonstrate that in conscious rats, pretreatment with pinacidil
and pretreatment with glibenclamide, although they obviously
have different mechanisms of action, may result in a very similar
final outcome with respect to arrhythmias and sudden cardiac
death during the acute phase of experimental myocardial in-
farction.
The major goal of therapeutic intervention during myocar-
dial infarction is to prevent lethal ventricular arrhythmias
and to preserve myocardial tissue from irreversible damage.
The former is a major problem during the acute phase of
myocardial infarction; the latter assumes great importance
when the patient has survived the first hours after infarc-
tion.
Since the discovery of KATP by Noma (1983), extensive
work has been devoted to elucidating its role in physiological
and pathological conditions. In the heart during normoxia,
this channel is found mainly in a closed, inactive form. How-
ever, as the intracellular ATP concentration falls as a result
of ischemia, the probability of the channel being open in-
creases, thereby increasing the significance of potassium cur-
rent during repolarization (Gasser and Vaughan-Jones,
1990). As a consequence, the myocardial action potential
duration is shortened, the voltage-dependent calcium influx
is decreased and cardiac work and oxygen consumption of the
myocardium are reduced, which leads to preservation of ATP
during ischemia. These changes may have a natural protec-
tive role in preserving the function of the heart for a longer
time during ischemia (Escande and Cavero, 1992).
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Several studies have suggested that administration of spe-
cific openers of KA channels during the early phase of
myocardial infarction can preserve myocardial function and
decrease infarct size (Lamping et al., 1984; Grover et al.,
1990; Toombs et al., 1992; Yao and Gross, 1994; Auchampach
and Gross, 1994). Other studies have yielded contradictory
results, suggesting either that such agents do not influence
the development ofinfarct size (Imai et al., 1988; Sakamoto et
al., 1989; Smallwood et al., 1993) or that they may even
increase it (Kitzen et al., 1992).
Theoretically, on the basis of the cellular electrophysiolog-
ical effects, KATP openers, as a result oftheir action potential
duration shortening effect, may inhibit the abnormal impulse
generation that frequently occurs several hours or days after
the onset of myocardial infarction (Lathrop et al., 1990; Bril
and Man, 1990; Spinelli et al., 1991). Accordingly, KATP ac-
tivators have been demonstrated to suppress arrhythmias
that are present 22 to 24 hr after coronary artery ligation
(Kerr et al., 1985). On the other hand, further shortening of
the action potential duration during the acute phase of myo-
cardial infarction may contribute to the aggravation of reen-
try type arrhythmias (Chi et al., 1990; Smallwood et al.,
1993). A similar proarrhythmic effect has been demonstrated
in isolated, perfused heart preparations in vitro (Wolleben et
al., 1989; Fagbemi et al., 1993; Di Diego and Antzelevitch,
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1993; Tosaki et al., 1993). However, the proarrhythmic effect
of KATP openers during the acute phase of experimental
myocardial infarction is also subject to question, because the
infarct size-limiting effect was also observed using smaller
doses that did not produce shortening of the action potential
duration in the normal myocardium (Grover et al., 1990;
D’Alonzo et al., 1994; Yao and Gross, 1994; Grover et al.,
1995).
Because of their electrophysiologic effect in the heart,
blockers 0fKATP ch8.IlIlelS, by inhibiting the shortening of the
action potential duration selectively in the ischemic myocar-
dium, would represent an antiarrhythmic treatment that is
more specific to ischemic tissues. The antiarrhythmic effect
has been demonstrated in in vitro experiments, using global
or regional ischemia in perfused hearts (Kantor et al., 1990;
Wolleben et al., 1989; Tosaki et al., 1993; D’Alonzo et al.,
1994). Relatively few data are available, however, from in
vivo experiments. These either demonstrate a protective ef-
fect against arrhythmias during the acute phase of experi-
mental myocardial infarction in rats (Ballagi-Pordany et at.,
1990; Zhang et at., 1991), or fail to show any beneficial effect
on the incidence of ventricular fibrillation developing in re-
sponse to a secondary ischemic insult in anesthetized dogs
with recent myocardial infarction (Chi et at., 1989).
Most of these in vivo experiments with KATP channel mod-
ulators involved only a few animals, which precluded any
statistical analysis of the different types and occurrence of
arrhythmias or of survival rate. Furthermore, these in vivo
experiments were performed during anesthesia, where the
anesthetic itself might interfere with the development of
ischemic damage or arrhythmias. The aim of our present
work was to study the effect of a well-known KATP channel
opener, pinacidil (Arena and Kass, 1989a; Martin and Chinn,
1990), on the outcome of the acute phase of experimental
myocardial infarction and to compare its effect to that of
glibenclamide, a KATP channel blocker (Sturgess et at., 1985;
Fosset et at., 1988) in a well-standardized model of arrhyth-
mias in conscious rats.
Materials and Methods
Animals. Male Sprague-Dawley CFY rats weighing 300 to 350 g
were used. Animals were fed commercial rat food pellet (Altromin,
G#{246}d#{246}ll#{246},Hungary) and were allowed to drink tap water ad libitum.
Animals were handled according to a protocol reviewed and approved
by the Ethical Committee of Research on Experimental Animals of
the Albert Szent-Gyorgyi Medical University, Szeged, Hungary.
Myocardial infarction in conscious rats. In a preliminary
surgery during ether anesthesia, after opening the thorax in the
fourth intercostal space, we placed a loose loop of atraumatic silk (K
890 H, 5-0, Ethicon, England) around the left main coronary artery,
about 2 mm from its origin (Lepr#{225}net al., 1983). The silk was led
through a cylinder-shaped polyethylene tubing, and the chest was
closed with the tubing remaining inside the thoracic cavity. During
its closure, the thorax was slightly compressed to stop pneumothorax
and to regain spontaneous ventilation. The animals quickly recov-
ered from this operation, and the mortality was negligible (less than
5%) because only a loose ligature was present around the coronary
artery at this time.
After complete recovery from the preliminary surgery (about 7-10
days) and using a brief ether narcosis, s.c. electrodes were stitched
under the skin to both sides of the chest wall, and the ends of the
loose silk loop were made free from under the skin. The animals were
taken into individual cages, and after about 2 hr of recovery from
ether anesthesia and of accommodation to their new place, drug
pretreatment was started and the loose silk ligature was tightened to
achieve acute coronary artery ligation in conscious, freely moving
animals.
The bipolar ECG was continuously recorded during the first 20
mm after coronary artery ligation. The survival rate and the mci-
dence and duration of arrhythmias were registered in accordance
with the Lambeth Conventions (Walker et al., 1988), i.e., VP, VT, and
other types of arrhythmias, including single VEBs, bigeminia, and
salvos. When VF occurred, no attempt was made to defibrillate the
animals.
An arrhythmia score was used to evaluate the incidence and
duration ofdifferent arrhythmias by giving a grade to the animals as
follows: 0 = no arrhythmia; 1 = <10 sec VT or other arrhythmias, no
VP; 2 = 11 to 30 sec VT or other arrhythmias, no VP; 3 = 31 to 90 sec
VT or other arrhythmias, no VF; 4 = 91 to 180 sec VT or other
arrhythmias and/or < 10 sec reversible VF; 5 = > 180 sec VT or other
arrhythmias and/or >10 sec reversible VF; 6 = irreversible VF.
In the rats surviving for 16 hr, the mass of the infarcted area was
measured by macroscopic staining (Nachlas and Shnitka, 1963). The
animals were anesthetized by pentobarbitone (60 mg/kg i.p.), and the
heart was excised and washed in isotonic saline solution. After being
sliced with razor into transversal slices approximately 1 mm thick,
the heart was stained in 0.1% nitroblue-tetrazolium dye (Fluka AG,
Switzerland). The wet weight of the infarcted, unstained myocar-
dium was expressed as a percentage of the total weight of the
ventricles.
Drug treatment. Pinacidil (0.03, 0.1, 0.3 or 1.0 mg/kg) was dis-
solved in isotonic saline solution (1 mI/kg) and was applied during 1
mm iv. into the tail vein in conscious animals 10 mm before coronary
artery ligation. Glibenclamide (5.0 mg/kg) was dissolved in a 1:1
mixture of dimethylsulfoxide and ethanol and was applied i.p. in a
volume of 100 ;.tl/kg 30 mm before coronary artery ligation. Half of
the control animals (n = 13) were given i.v. 1 mI/kg isotonic saline
solution as a vehicle; the others (n = 12) were given the solvent for
glibenclamide (100 pg/kg i.p.). No differences were found in survival
rate or occurrence of arrhythmias in the vehicle-treated groups, so
they were combined for the final statistical calculations.
Statistical analysis. For the statistical analysis of the survival
rate and the incidence of arrhythmias, the chi-square test was ap-
plied. The arrhythmia score was compared using Gehan’s general-
ized Wilcoxon test (Knapp and Wise, 1985). The other parameters
were expressed as mean ± SE. and, after analysis of variance
(one-way ANOVA), were compared by using the modified t statistic of
Wallenstein et al. (1980).
Results
Pinacidil, given i.v. 10 mm before coronary artery ligation
in conscious rats, dose-dependently increased the HR, mea-
sured just before ligation (fig. 1). In the control group, the
first 15 min of coronary occlusion was characterized by a
moderate tachycardia (fig. 1). Pinacidil pretreatment did not
influence the HR response during the acute phase of myocar-
dial infarction. Glibenclamide, in the dose applied 30 mm
before coronary artery ligation, did not influence the basal
HR or its response during the first 15 mm of myocardial
ischemia (fig. 1).
Coronary artery ligation in conscious rats resulted in se-
vere arrhythmias that appeared around the fourth or fifth
minute, but if the animal survived the acute phase of infarc-
tion, arrhythmias were rarely seen after the twelfth mm. In
all of the control rats, some kind of dysrhythmia developed
during the first 15 mm of coronary occlusion (table 1). Out of
the 25 animals, VF failed to develop in only 6 rats, and in 15
cases the VF was irreversible. Out of the 10 animals that
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Fig. 1. Effect of pinacidil (PIN) and glibenclamide (GLIB) on the basal
HR and its alteration during the acute phase of myocardial infarction in
conscious rats. Pinacidil was applied i.v. 10 mm, and Glibenclamide
was given i.p. 30 mm, before the start of coronary artery ligation.
indicates a statistically significant difference from the control group.
survived the first 15 mm of coronary occlusion, 4 died during
the next 16 hr (table 1).
Pinacidil pretreatment (except for the smallest dose) in-
creased the survival rate during the first 15 mm of occlusion;
moreover, some animals did not develop arrhythmias at all
(table 1). Although pinacidil did not decrease significantly
the incidence of VF at each dose, the chance for spontaneous
defibrillation was increased, and the occurrence of irrevers-
ible VF was smaller (e.g., 54% after 0.3 mg/kg pinacidil vs.
79% in controls). Significant effects were even achieved by
0.1 mg/kg pinacidil, which did not produce maximal increases
in HR (fig. 1; table 1).
Glibenclamide significantly increased the survival rate
both during the first 15 mm and during the subsequent 16 hr
of myocardial infarction (table 1). The pretreatment de-
creased the incidence of VF and VT and increased the num-
ber of animals that did not develop any arrhythmia during
the first 15 mm after coronary artery ligation (table 1).
The arrhythmia score, which expressed the severity and
duration of arrhythmias as well as the surviving rate in a
single number, was also significantly decreased after both
pinacidil and glibenclamide pretreatments (table 1).
There was no significant difference between the control
and the drug-treated groups in the appearance of the first
arrhythmia, determined in the animals that did show some
kind of dysrhythmia (not presented in the tables). However,
as a result of the increased number of animals that did not
develop arrhythmias at all, the onset of the first arrhythmia
was delayed and the duration of the arrhythmic period was
shortened after both pinacidil and glibenclamide pretreat-
ments (table 2). The length ofdifferent arrhythmic attacks in
the surviving animals was decreased as well (table 2).
We lost the majority of the control animals within 15 mm
after coronary artery ligation. This time was too short for the
animals to develop histologic change detectable by nitroblue-
tetrazolium staining, so we could not determine the infarct
size in those animals that died during the acute phase of
myocardial infarction. The infarct size in the control animals
that survived for 16 hr was 32.4% ± 5.3% (n = 6), and
infarcts extended to the anterior and lateral free wall of the
left ventricle. There was a tendency ofinfarct size to decrease
after pinacidil pretreatment. It was 34.5% ± 3.7% (n = 9),
24.0% ± 3.8% (n = 11), and 21.9% ± 8.0% (n = 8) after 0.1,
0.3 and 1 mg/kg pinacidil, respectively. Glibenclamide pre-
treatment resulted in an infarct size involving 24.5% ± 5.3%
(n = 14) of the wet weight of the ventricles.
Discussion
Coronary artery ligation in rats is a widely used and widely
accepted method for studying the pathophysiology of acute
myocardial infarction and for investigating various antiar-
rhythmic and “anti-ischemic” interventions. Such a method
is relatively simple, is quick, and makes it possible to include
sufficient numbers of animals for the statistical analysis of
parameters, such as the incidence of arrhythmias or sudden
cardiac death. Using the modified method, i.e. ligation of the
coronary artery by a previously placed loose silk loop, we
were able to avoid the use of any anesthetic agent during
coronary artery ligation. Therefore, the acute phase of myo-
cardial infarction could be induced in conscious rats with
intact autonomic reflexes.
The present results demonstrate that pretreatment with
either pinacidil, a KA channel opener, or glibenclamide, a
KA channel inhibitor, may offer significant protective effect
during the acute phase ofexperimental myocardial infarction
in conscious rats. Both drugs were highly effective in decreas-
ing the incidence of life-threatening arrhythmias and in-
creasing the number of animals that survived without devel-
oping any arrhythmia during the acute phase of myocardial
infarction.
The protection afforded by pinacidil pretreatment occurred
in spite of a very intense tachycardia. This effect was prob-
ably due to the intact baroreflex control in conscious animals
and occurred as a consequence of the well-known blood pres-
sure-lowering effect of pinacidil. Tachycardia itself could in-
crease myocardial oxygen consumption and decrease the ef-
ficacy of cardiac work; it is considered undesirable during
acute myocardial infarction (Bernier et at., 1989). On the
other hand, sinus tachycardia may work as an overdrive
suppression during ventricular arrhythmias and may con-
tribute significantly to the antiarrhythmic effect of pinacidil
in conscious rats. Such a mechanism may play a role only in
conscious animals, however, because in an anesthetized rat
model, pinacidil afforded similar protective effects against
reperfusion-induced arrhythmias while having no significant
tachycardiac effects (Baczk#{243}et at., 1994).
The mechanism of the significant antiarrhythmic effect
offered by pinacidil in our experiments is not known; both
peripheral and cardiac effects may be involved. The periph-
eral vasodilation induced by pinacidil may decrease the total
peripheral resistance and thereby reduce cardiac work. Such
an unloading may help the ischemic myocardium to survive
the most critical phase of myocardial infarction. However,
this mechanism may be significant mainly in the later phase
of myocardial infarction (days or weeks after coronary liga-
tion), whereas decreasing the blood pressure during the
acute phase ofmyocardial infarction would rather precipitate
arrhythmias, because of the decrease in coronary perfusion
pressure. This was demonstrated in our previous experi-
ments in anesthetized rats during a short coronary artery
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Results are mean ± SE.
Asterisks denote statistically significant difference calculated by the modified t statistic: *D < .05,  < .01 , ‘P < .001.
a Because of the small number of surviving animals in this group, the duration and length of arrhythmias were not calculated.
For other details, see table 1.
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TABLE 1
Effect of pinacidil and glibenclamide on the survival rate and the incidence of arrhythmias during the acute phase of myocardial
infarction in conscious rats
0 Survived SurvivedGroup ose  15 mm 16 hrsmw g, (Noi%) (No.1%) None
Incidence of Arrhythmias (Noi%)
Arrhythmia Score
VF VT 0ther Bradyb
Control 25 10/40 6/24 0/0 19/76 24/96 15/60 6/24 5.1 ± 0.27
Pinacidil 0.03 9 2/22 1/11 0/0 8/89 9/100 3/33 1/11 5.3 ± 0.55
0.10 15 10/67 9/60 * 3/20  6/40  9/60  7/47 1/7 3.0 ± 0.65 **
0.30 20 14/70 * 11/55 * 4/20 * 11/55 13/65 * 11/55 7/35 3.6 ± 0.52 **
1.00 12 8/67 8/67 ** 4/33** 5/42 * 5/42 *** 3/25* 2/1 7 2.7 ± 0.81 **
Glibenclamide 5.00 16 14/87** 14/87* 5/31** 4/25** 9/56 ** 9/56 1/6 2.4 ± 0.56***
a Arrhythmias, e.g. VEBs, salvos, and bigeminia.
b Bradycardia.
Asterisks denote statistically significant difference calculated by the chi-square method or by Gehan’s generalized wilcoxon test : P < .05, * * < o , ‘P < .001.
n = total number of animals; No. = number of animals exhibiting the given response.
TABLE 2
Effect of pinacidil and glibenclamide on the appearance and length of arrhythmias in conscious rats that survived the acute phase of
regional myocardial ischemia
Group Dose(mg/kg) (1
Appearance of
Arrtiythmias (mm)
Duration of
Arrhythmias (mm)
Length of arrhyt hmic attacks (sec)
VF VT Other Total
Control 10 5.03 ± 0.49 4.87 ± 0.70 24 ± 12.6 44 ± 16.3 50 ± 12.2 118 ± 29.6
Pinacidil o.o3a
0.1 0
0.30
2
10
14
4.02 ± 0.36
9.1 7 ± 1 .36*
8.39 ± 1.19
1 .97 ± 0.79*
3.25 ± 0.83
5 ± 5.0
21 ± 8.7
8 ± 3#{149}9*
21 ± 10.9
4.6*
34 ± 11.3
24 ± 9.6*
77 ± 27.1
1.00
5.00
8
14
1 1 .9 ± 1 .50
8.17 ± 1.43
0.75 ± 0.38
3.35 ± 1.01
9 ± 8.8
4 ± 3.1
1 ± 1 #{149}3*
25 ± 8.6
o ± 5#{149}3*
31 ± 11.1
20 ± 14.6*
61 ± 20.5
ligation followed by reperfusion (Baczk#{243}et at., 1994), wherein
a large dose of pinacidil that induced long-lasting hypoten-
sion did not offer any protective effect against reperfusion-
induced arrhythmias.
Coronary collateral blood flow may significantly limit the
extent of myocardial damage (Nienaber et at., 1983). The
vasodilating effect of pinacidil at the level of collaterals could
limit the development of infarct size, and such a mechanism
could result in a decreased incidence of arrhythmias. Al-
though we did not measure collateral circulation in our ex-
periments, the very limited collateral blood flow in this spe-
cies (Maxwell et at., 1987) makes it unlikely that such a
mechanism is responsible. Even in dogs, where well-devel-
oped collaterals exist, pinacidil did not influence collateral
blood flow during ischemia (Auchampach and Gross, 1994).
In spite ofthe fact that pinacidil pretreatment significantly
increased the survival rate both during the acute phase (first
15 mm) and in the second phase (until the 16th hour) of
myocardial infarction, the infarct size was only slightly de-
creased. The present experiments, however, were devoted to
investigating the acute phase arrhythmias, not the extent of
infarct size in the rat. We suppose that having a control
group with a low survival rate (as in the present experi-
ments, where only 6 out of 25 animals survived), we may
have underestimated the infarct size because of losing ani-
mals with large evolving myocardial infarction before the
infarct size could be determined. On the other hand, if the
drug treatment increased the chance to survive the first
phase of myocardial infarction, we could measure infarct size
in more animals, including those that had larger myocardial
infarction. Therefore, we may have overestimated infarct size
after an effective drug treatment (Lepr#{225}net at., 1983). For
the investigation of infarct size, it would be preferable to
produce smaller myocardial infarction that results in a
higher survival rate in the control group as well. Experimen-
tel findings in dogs suggest that KA openers may actually
decrease infarct size (Gross et al., 1989; Grover et at., 1990;
Auchampach and Gross, 1994).
In theory the electrophysiological effects produced by KATP
channel openers, i.e., shortening of the action potential du-
ration, may result in proarrhythmic effect and may precipi-
tate arrhythmias during the acute phase of myocardial in-
farction. Indeed, Chi et al. (1990) demonstrated that pinacidil
produced profibrillatory action in a subset of dogs unrespon-
sive to programmed electrical stimulation during the sub-
acute phase of anterior myocardial infarction and known to
be at low risk of VF due to a second acute posterolateral
ischemia. Others have shown that pinacidil, after intracoro-
nary administration, may increase the incidence or the se-
verity ofventricular arrhythmias (Smallwood et at., 1993). In
some in vitro experiments using global ischemia of perfused
heart, an increased incidence of arrhythmias during isch-
emia or reperfusion was also reported (Wolleben et al., 1989;
Fagbemi et at., 1993; Tosaki et at., 1993; Kaiser et al., 1994).
In these experiments, however, relatively high concentra-
tions of pinacidil or other KA channel openers were ap-
plied- higher than those reached in patients after long-term
treatment with a high dose of pinacidil (Friedel and Brogden,
1990).
Other investigations, using smaller doses of KATP channel
openers, have demonstrated an antiarrhythmic effect in ad-
dition to limitation of the infarct size (Grover et al., 1990;
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D’Alonzo et al., 1994). In the present experiments in con-
scious rats, we also found a protective effect against arrhyth-
mias during the acute phase of myocardial infarction.
KATP channel openers in therapeutic concentrations that
evoke hypotension do not produce significant electrophysi-
ologic effects in the normally oxygenated myocardium (Arena
and Kass, 1989b; Nakayama et at., 1990). On the other hand,
their effect is enhanced during myocardial ischemia when
intracellular ATP concentration falls (Arena and Kass,
1989b; Nakayama et al., 1990; Martin and Chinn, 1990).
Channel opening would result in improved repolarization
and the inhibition of voltage-dependent calcium influx into
myocardial cells, thereby decreasing contractile activity
within the ischemic zone (Cole et at., 1991). This effect may
preserve energy and improve tolerance to the ischemic insult.
In this respect, what we have measured as an “antiarrhyth-
mic” effect probably is not only a direct effect, mediated by
ionic currents through the membrane, but can also be attrib-
uted to an increase in tolerance to ischemia.
The progression of myocardial ischemia is not homoge-
neous, not even in the occluded area, and may lead to a
nonhomogeneous shortening of the action potential duration.
This increased electrical inhomogeneity may be involved as
an electrophysiologic substrate to develop ventricular ar-
rhythmias and YE’ during the acute phase of myocardial
infarction (Janse and Wit, 1989). KA openers may decrease
electric inhomogeneity within the ischemic area, possibly by
further shortening the action potential duration in “less isch-
emic” fibers. The electrophysiologic difference between Se-
verely ischemic and less severely damaged fibers could be
diminished by this means. Such a mechanism might contrib-
ute to the antiarrhythmic effect observed in our experiments
during the acute phase of infarction, when the electrophysi-
ology of the myocardium is most unstable.
KATP inhibitors, on the other hand, may inhibit K loss
from jeopardized cells and inhibit nonuniform shortening of
the action potential duration during the progression of myo-
cardial ischemia (Tweedie et at., 1993; MacKenzie et at.,
1993). Such an effect produced by glibenclamide, in the way
opposite that described above for pinacidil, could alleviate
the increase in electric inhomogeneity between the ischemic
and normally oxygenated tissues and might inhibit the sub-
strate for reentrant pathways, resulting in antiarrhythmic,
antifibrillatory action during the acute phase of myocardial
infarction. Although we did not perform dose-response eval-
uation for the antiarrhythmic effects of glibenclamide, the
present data are in good agreement with the results of Ba!-
lagi-Pordany et al. (1990). They found a decreased incidence
of arrhythmias in anesthetized rats after applying 3 to 10
j.molIkg of glibenclamide i.p.. It should be emphasized that
the protective effect by glibenclamide occurred in spite of its
hypoglycemic action, which may exacerbate the antiarrhyth-
mic effect.
The present results in conscious rats are in good correla-
tion with that described by D’Alonzo et at. (1994), showing
both potassium channel openers and glibenclamide to have
potential antiarrhythmic activity during coronary artery li-
gation and reperfusion in an isolated, perfused rat heart
model. Their suggestion is that these compounds may influ-
ence different types of arrhythmias that are linked with
myocardial ischemia. Accordingly, KATP channel openers
may abolish triggered activity, whereas glibenclamide may
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reduce reentry. This explanation may also be in accordance
with our in vivo experiments and may account for the marked
antiarrhythmic and antifibrillatory action.
It should be noted that many investigators have described
KATP openers as proarrhythmic during the acute phase of
myocardial infarction (Wolleben et at., 1989; Fagbemi et at.,
1993; Tosaki et at., 1993; Chi et at., 1990; Smallwood et al.,
1993), whereas glibenclamide has been found to increase
infarct size (Cole et al., 1991; Thornton et al., 1993). The
conflicting effects on arrhythmias and on the development of
myocardial damage may be related to different models of
myocardia! infarction, e.g., global or regional ischemia, in
vitro or in vivo experiments, and so on.
The present results demonstrate that both opening and
closing KATP channels by pinacidil and glibenclamide pre-
treatments, respectively, may offer a protective effect against
life-threatening arrhythmias and increase the chance to sur-
vive the acute phase of myocardial infarction in conscious
rats. The mechanism of these actions needs further investi-
gations, but inhibition of the increase in electric inhomoge-
neity during acute myocardial ischemia may be involved in
both cases. An increased tolerance to the development of
myocardial ischemia after pinacidil treatment may also be
responsible. Further investigation of more selective com-
pounds- compounds that have less significant vascular or
hypoglycemic effects and more specific action on myocardial
cells-may help to elucidate this question.
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